Home

Aoife Brennan

CIK 1714563 · President and CEO · last filed 2026-06-12

Aoife Brennan is a President and CEO who has filed 30 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for CLYM, was dated Jun 30, 2026. Across all open-market trades the lifetime net is −$139.2K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

30

Lifetime Open-Market Net

-$139.2K

Filer Profile

Reported Address
200 SIDNEY STREET, SUITE 320
C/O SYNLOGIC, INC.
CAMBRIDGE, MA 02139
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XLO Director — $8.93 — $0 3 2026-06-12
Climb Bio, Inc. (ELYM) Delisted President and CEO 48,132 $5.11 $246.0K -$25.2K 4 2026-01-08
KYNTRA BIO, INC. (FGEN) Delisted Director 1,118 $9.75 $10.9K -$81.4K 5 2024-06-06
SYNLOGIC, INC. (SYBX) Delisted President and CEO 17,087 $0.69 $11.8K -$32.7K 11 2023-11-14
Ra Pharmaceuticals, Inc. (RARX) Delisted Director — — — $0 3 2020-04-03

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-30 CLYM Notice (144) −30,902 -$407.0K EDGAR
2026-06-12 XLO Grant (A) — $0 EDGAR
2026-01-08 Climb Bio, Inc. (ELYM) Delisted Grant (A) — $0 EDGAR
2025-07-01 Climb Bio, Inc. (ELYM) Delisted Mixed +48,132 -$25.2K EDGAR
2025-06-12 XLO Grant (A) — $0 EDGAR
2025-01-15 Climb Bio, Inc. (ELYM) Delisted Grant (A) — $0 EDGAR
2024-06-27 Climb Bio, Inc. (ELYM) Delisted Grant (A) — $0 EDGAR
2024-06-17 XLO Grant (A) — $0 EDGAR
2024-06-06 KYNTRA BIO, INC. (FGEN) Delisted Grant (A) — $0 EDGAR
2024-04-22 SYNLOGIC, INC. (SYBX) Delisted Notice (144) −88,293 -$161.6K EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.